CME

Faculty: Naim Alkhouri, MD, FAASLD, DABOM

Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically significant portal hypertension without the need for biopsy. Management focuses on preventing hepatic decompensation through beta-blocker therapy (particularly carvedilol), nutritional optimization, and hepatocellular carcinoma surveillance. Novel therapies such as efruxifermin and resmetirom may reverse fibrosis. This evidence-driven approach aims to improve outcomes in patients with MASH-related compensated cirrhosis.

Guest: Joshua Richter, MD

This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge longstanding treatment gaps for patients exhibiting inadequate responses to the conventional medications. This activity will help providers differentiate CELMoDs from newer, alternative agents used in MM, examine the latest clinical trial data supporting the adoption of these drugs, and readily identify the clinical circumstances in which their use would be warranted in clinical practice. By participating, clinicians can additionally examine the utility of emerging combination strategies that maximize the therapeutic synergies of CELMoDs with other newer treatment classes, such as EZH2 inhibitors. In doing so, community hematologist-oncologists can substantially extend patient survival and improve the patient experience through each phase of the MM care continuum.

Faculty: Michael E. Thase, MD

Faculty: Andrew Krystal, MD

Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia.

Host: Stephen Chrzanowski, MD, PhD

Guest: Aravindhan Veerapandiyan, MD

Corticosteroids remain a cornerstone in Duchenne muscular dystrophy (DMD) management, but evolving therapies demand a more nuanced approach. This case-based activity explores how to proactively monitor and manage corticosteroid-associated side effects through interdisciplinary care coordination. Strengthen your care strategy as the DMD treatment landscape continues to shift.

Faculty: prof. Hiddo Heerspink

Faculty: Peter Rossing, MD, DMSc

Faculty: Paola Fioretto, MD

Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and guideline recommendations. Attention is now shifting to CKD in type 1 diabetes. Ongoing trials, such as FINE-ONE with finerenone, may soon expand therapeutic options and ensure no patient is left behind.

Host: Lisa Phipps, PharmD, PhD

Guest: Michael Sprintz, DO, DFASAM

Guest: Amanda Zimmerman, PA-C

This Opioid Analgesic REMS webcast provides an FDA Blueprint-aligned learning experience to support safe, compassionate pain management through thorough assessment and individualized treatment planning. Also covered is counseling on safe opioid use, storage, and disposal; monitoring for misuse; and screening and management of opioid use disorder.

Faculty: Rajiv Agarwal, MBBS, MD, FASN, BRCU

Faculty: Prof. Dr. Francesc Xavier Cos Claramunt

This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence from the CONFIDENCE and other trials, the discussion highlights the benefits and safety of early combination therapy with finerenone and SGLT2i, and GLP-1 receptor agonists. Practical strategies are shared to support primary care teams in integrating these therapies and reducing long-term cardio-kidney-metabolic risk.

Guest: Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM

Guest: Radhika S. Breaden, MD, MPH, DABMS, DABOM

Guest: H-C Carol Huang, BHB, MBChB, FRACP

Guest: Babak Mokhlesi, MD, MSc

Guest: Amanda J. Piper, PhD

Guest: Rafael Sepulveda, MD, DABMS, DABOM

Guest: Audrey Wells, MD

On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strategies for prioritizing weight loss to improve OSA management among select patients.

Faculty: Christoph U. Correll, MD

Faculty: Jonathan M. Meyer

Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

Faculty: Neelam Goyal, MD

Faculty: Christyn Edmundson, MD

This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making.